Adalimumab biosimilar ABP 501 is equally effective and safe in long-term management of inflammatory bowel diseases patients when used as first biologic treatment or as replace of t... by Giammarco Mocci, Arianna Cingolani, Giorgia Orrù, Carla Felice, Francesca Maria Onidi, Gianmarco Lombardi, Davide Checchin, Raffaele Colucci, Laurino Grossi, Antonio Ferronato, Chiara Rocchi, Marta Ascolani, Paolo Usai Satta, Lucia Fanini, Stefano Pilati, Antonio Tursi, Antonio Tursi

Get full text